# Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

> **NCT06313008** · NA · COMPLETED · sponsor: **Damanhour University** · enrollment: 120 (actual)

## Conditions studied

- Coronary Artery Disease
- Type 2 Diabetes

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Vildagliptin 50 MG

## Key facts

- **NCT ID:** NCT06313008
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-10
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313008, "Empagliflozin Versus Vildagliptin in CAD Patients With T2DM". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06313008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*